Showing 1 - 10 of 39
Motivated by policy events experienced during the last two decades by the European natural gas industry, this paper develops a simple model for analyzing the interaction between gas release and capacity investment programs as tools to improve the performance of imperfectly competitive markets....
Persistent link: https://www.econbiz.de/10010706828
This paper develops a simple model for examining the gas-release programs as the unique tool to improve the performance of imperfectly competitive natural gas markets. We study the "artificial" duopoly effect created by first the incumbent and then by a regulator who introduces a gas-release...
Persistent link: https://www.econbiz.de/10010707050
Persistent link: https://www.econbiz.de/10003479139
Motivated by policy events experienced during the last two decades by the European natural gas industry, this paper develops a simple model for analyzing the interaction between gas release and capacity investment programs as tools to improve the performance of imperfectly competitive markets....
Persistent link: https://www.econbiz.de/10011039531
Motivated by recent policy events experienced by the European natural gas industry, this paper develops a simple model for analyzing the interaction between gas release and capacity investment programs as tools to improve the performance of imperfectly competitive markets. We consider a regional...
Persistent link: https://www.econbiz.de/10008752845
Motivated by recent policy events experienced by the European natural gas industry, this paper develops a simple model for analyzing the interaction between gas release and capacity investment programs as tools to improve the performance of imperfectly competitive markets. We consider a regional...
Persistent link: https://www.econbiz.de/10008764516
Persistent link: https://www.econbiz.de/10009688110
Persistent link: https://www.econbiz.de/10008749013
After generics, which are copies of chemical medicines, "copies" of already patented biologics (biosimilars) are entering the biologics market and competing with their originators. Many uncertainties remain regarding the development of this newly emerging market, and the ability of biosimilars...
Persistent link: https://www.econbiz.de/10011105187
This paper addresses the question of what options are available to regulate the sector in the near future. In order to answer this question, the paper focuses on the problem of investment and innovation in an ex ante regulated sector. Relying on existing literature, we argue that ex ante...
Persistent link: https://www.econbiz.de/10011166384